The HER2-positive breast cancer treatment paradigm has undergone considerable change in recent years and is expected to evolve further as more novel therapies enter the market. The enthusiastic…
Market Outlook Therapeutic options for gastroesophageal cancer are limited, with only two targeted agents approved for the treatment of gastric and GEJ adenocarcinoma (neither agent is approved…
Immune checkpoint inhibitors continue to revolutionize the treatment of a wide range of solid-tumor and hematological malignancies, with a growing list of approvals and label expansions. The Immune…
Despite the extensive armamentarium of chronic pain therapies, which is increasingly subject to generic competition, the chronic pain market continues to represent a notable commercial…
NSCLC is one of the most dynamic indications in oncology. In the United States, the FDAapproved six new therapies for NSCLC in 2015 and, in 2016, granted approval to Tecentriq (Roche/Genentech…
Painful diabetic neuropathy (PDN), a subset of diabetic neuropathy; affects approximately seven million people in the United States and major European markets. The primary goal of treating PDN is…
Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-…
Hormonal therapy is the mainstay of prostate cancer, in all stages of disease and clinical settings. The adoption of novel hormonal agents, Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/…
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that usually affects children but can persist or start in adulthood. For many years, the treatment landscape has remained…
The tumor necrosis factor (TNF) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. However, several…
Once limited to ankylosing spondylitis (AS), the axial spondyloarthritis (AxSpA) therapy market is undergoing rapid change as the definition of the disease expands beyond those with detectable…
Because no current therapy for type 2 diabetes offers disease-modifying capabilities, there is high unmet need for drugs that can effectively control the disease. DRG’s Type 2 Diabetes Unmet…
Following the European Medicines Agency’s approvals of the PDE-4 inhibitor Otezla and the IL-17 inhibitor Cosentyx for psoriatic arthritis (PsA), treatment of this disease in the EU5 has begun to…
IBS-D is a highly prevalent disorder regularly encountered in general practice that is marked by excessive defecation and abdominal pain/discomfort. Currently, its etiology and pathophysiology are…
Gram-negative infections (GNIs) account for a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these…